Table 2. Detection frequency of anti-FIRs antibodies and clinically used tumor markers in the sera of gastrointestinal carcinoma based on clinical stages.
| Anti-FIRs antibodies | Anti-p53 antibodies | CEA | CA19-9 | CYFRA | |
|---|---|---|---|---|---|
| Colorectal cancer | 28/87 (32.2%) | 21/84 (25.0) | 35/87 (40.2) | 31/87 (35.6) | - |
| Dukes A,B | 18/49 (36.7) | 8/48 (16.7) | 14/49 (28.6) | 11/49 (22.4) | - |
| Dukes C,D | 9/38 (23.7) | 13/36 (36.1) | 21/38 (55.3) | 20/38 (52.6) | - |
| Esophageal cancer | 7/27 (25.9) | 4/27 (14.8) | 5/27 (18.5) | - | 6/27 (22.2) |
| stages 0. I. II | 5/16 (31.3) | 1/16 (6.3) | 4/16 (25) | - | 4/16 (25) |
| stages III. IV | 2/11 (18.2) | 3/11 (27.3) | 1/11 (9.1) | - | 2/11 (18.2) |
| Gastric cancer | 0/20 (0) | - | - | - | - |
| stages 0. I. II | 0/10 (0) | - | - | - | - |
| stages III. IV | 0/10 (0) | - | - | - | - |
| Healthy subject | 0/42 (0) | 4/42 (9.5) | 0/42 (0) | 1/42 (2.4) | - |